Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „ponesimod“
Suchtreffer
Begriffe & Kennungen
Ponvory · 4.5 · 11 No dose adjustment is needed when ponesimod is co-administered with strong CYP3A4 and UGT1A1 inducers. Co-a
Eintrag öffnenPonvory · 4.5 · Co-administration of ponesimod, with an oral hormonal contraceptive (containing 1 mg norethisterone/norethindr
Eintrag öffnenPonvory · 4.5 · Effect of other medicinal products on ponesimod
Eintrag öffnenPonvory · 4.5 · Effect of ponesimod on other medicinal products
Eintrag öffnenPonvory · 4.5 · In a drug-drug interaction study, the up-titration regimen of ponesimod (see section 4.2) was administered to
Eintrag öffnenPonvory · 4.5 · Ponesimod and its metabolites are unlikely to show any clinically relevant drug-drug interaction potential for
Eintrag öffnenPonvory · 4.5 · Ponesimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive th
Eintrag öffnenPonvory · 4.5 · Ponesimod has not been studied in patients taking QT prolonging medicinal products (see section 4.4).
Eintrag öffnenPonvory · 4.5 · Ponesimod is not a substrate of P-gp, BCRP, OATP1B1 or OATP1B3 transporters. Medicinal products that are inhib
Eintrag öffnenPonvory · 4.5 · The negative chronotropic effect of co-administration of ponesimod and propranolol was evaluated in a dedicate
Eintrag öffnenPonvory · 4.5 · Vaccinations may be less effective if administered while being treated with ponesimod and up to 1 week after i
Eintrag öffnenPonvory · 4.8 · 14 Initiation of ponesimod treatment has been associated with transient AV conduction delays that follow a sim
Eintrag öffnenPonvory · 4.8 · 15 Hypertension was reported as an adverse reaction in 10.1% of ponesimod-treated patients and in 9.0% of pati
Eintrag öffnenPonvory · 4.8 · Adverse reactions reported with ponesimod in controlled clinical trials and uncontrolled extension trials are
Eintrag öffnenPonvory · 4.8 · Blood lymphocyte count reduction In OPTIMUM, 3.2% of ponesimod-treated patients compared to none of the patien
Eintrag öffnenPonvory · 4.8 · In OPTIMUM, the rate of herpetic infections was not different between the ponesimod-treated patients and those
Eintrag öffnenPonvory · 4.8 · Increased blood pressure In OPTIMUM, ponesimod-treated patients had an average increase of 2.9 mmHg in systoli
Eintrag öffnenPonvory · 4.8 · Macular oedema In OPTIMUM, macular oedema was reported in 1.1% of ponesimod-treated patients compared to none
Eintrag öffnenponesimod
Eintrag öffnenponesimod
Eintrag öffnen